Ultrapure dialysate reduces plasma levels of β2- microglobulin and pentosidine in hemodialysis patients

Blood Purification

Volumn 23, Issue 4, 2005, Pages 311-316

  Furuya, Ryuichi ^a   Kumagai, Hiromichi ^b   Takahashi, Masaaki ^c   Sano, Koji ^a   Hishida, Akira ^c  

^a Iwata City Hospital   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2 Microglobulin; Chronic inflammation; Dialysate purity; Pentosidine

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 6; PENTOSIDINE; POLYSULFONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

AGED; AMYLOIDOSIS; ARGININE; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; ENDOTOXINS; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 24944517433     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086554     Document Type: Article

References (33)

1. 2-microglobulin. Biochem Biophys Res Commun 1985;129:701-706.
2. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
3. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994;93:521-528.
4. 2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996;93:2353-2358.
5. 2-microglobulin is modified with Nε-(carboxymethyl) lysine in dialysis-related amyloidosis. Kidney Int 1996;50:1303-1309.
6. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduced the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101.
7. Nakai S, Iseki K, Tabei K, Kubo K, Masakane I, Fushimi K, Kikuchi K, Shinzato T, Sanaka T, Akiba T: Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 2001;38(suppl 1):S212-216.
8. 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996;7:472-478.
9. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, Greca GL, Orlandini G, the Italian Cooperative Dialysis Study Group: Effects of different membranes and dialysis technologies on patients' treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293-1302.
10. 2- microglobulin removal by different hemodialysis membranes: A six-year follow-up. Nephron 1993;63:368-369.
11. Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of AB amyloidosis: Effects of biocompatibility and flux. Nephrol Dial Transplant 2000;15:840-845.
12. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C: Results from EuCliD (European Clinical Dialysis Database): Impact of shifting treatment modality. Int J Artif Organs 2002;25:1049-1060.
13. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Kidney Int 1999;55:2478-2492.
14. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999-1008.
15. Sitter T, Bergner A, Schiffl H: Dialysate-related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207-1211.
16. Schiffl H, Lang SM, Stratakis D, Fischer R: Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001;16:1863-1869.
17. Hsu PY, Lin CL, Yu CC, Chien CC, Hsiau TG, Sun TH, Yang CW: Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - A prospective cross-over study. J Nephrol 2004;17:693-700.
18. Depner TA, Daugirdas JT: Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol 1996;7:780-785.
19. Takahashi M, Hoshino H, Kushida K, Kawana K, Inoue T: Direct quantification of pentosidine in urine and serum by HPLC with column switching. Clin Chem 1996;42:1439-1444.
20. Wizemann V, Lotz C, Techert F, Uthoff S: On-line hemodiafiltration versus low-flux hemodialysis. A prospective randomized study. Nephrol Dial Transplant 2001;15(suppl 1):43-48.
21. 2-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 2003;64:1522-1528.
22. 2-Microglobulin amyloidosis: Effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol 2002;13:S72-S77.
23. Baz M, Durand C, Ragon A, Jaber K, Andrieu D, Merzouk T, Purgus R, Olmer M, Reynier JP, Berland Y: Using ultrapure water in nemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991;14:681-685.
24. Kleophas W, Haastert B, Backus G, Hilgers P, Westhoff A, van Endert G: Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant 1998;13:3118-3125.
25. Izuhara Y, Miyata T, Saito K, Ishikawa N, Kakuta T, Nangaku M, Yoshida H, Saito A, Kurokawa K, van Ypersele de Strihou C: Ultrapure dialysate decreases plasma pentosidine, a marker of 'carbonyl stress'. Am J Kidney Dis 2004;43:1024-1029.
26. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887.
27. Gerdemann A. Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant 2002;17:1045-1049.
28. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-1181.
29. Witko-Sarsat V. Friedlander M, Capelleire-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
30. 2-Microglobulin-associated amyloidosis: A vanishing complication of long-term hemodialysis? Kidney Int 1997;52:1077-1083.
31. Lederer SR, Schffl H: Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002;91:452-455.
32. Hoenich NA, Levin R: The implications of water quality in hemodialysis. Semin Dial 2003;16:492-497.
33. Rahmati MA, Homel P, Hoenich NA, Levin R, Kaysen GA, Levin NW: The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs 2004;27:723-727.